Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers
This article was originally published in RPM Report
Executive Summary
An abbreviated pathway for follow-on biologics just missed getting tacked onto the FDA user fee/drug reform legislation. It will be years before proponents get another shot at creating an abbreviated approval pathway for the biotech copycats. So who won and who lost?
You may also be interested in...
In Brave New World of Follow-On Biologics, Can't We Do Better Than 1984?
Congress has moved into the final horse-trading phase of policy development regarding incentives for innovators and biosimilar product developers. The main question on Capitol Hill is what compromise can generate enough support to survive the political process. Jeffrey MOe, a Duke business school professor with experience developing incentives for drug development policy, suggest Congress should reflect before forging its political decision.
Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't
The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.
Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't
The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.